Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Immune checkpoint inhibitors (ICIs) have emerged as paradigm shifting treatment options for a number of cancers. Six antibodies targeting the immune checkpoint proteins programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) or cytotoxic T-lymphocyte associated protein 4 (CTLA4) have been approved. | Case report Reinitiating pembrolizumab treatment after small bowel perforation